已收盘 08-07 16:00:00 美东时间
-0.031
-3.52%
Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.
07-18 00:07
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Elutia (NASDAQ:ELUT) is gearing up to announce its quarterly earnings on Wednes...
03-11 02:01
Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid
03-04 21:07
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Elutia Inc. developed a novel method to measure antibiotic release from biologic envelopes, enabling faster and cost-effective development and testing of its EluPro portfolio. The validated in vitro approach provides reliable results in 30 hours, supporting drug-eluting biomatrix innovation and regulatory compliance.
2025-05-28 12:00
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT)
2024-09-18 20:09
Cantor Fitzgerald analyst Ross Osborn reiterates Elutia (NASDAQ:ELUT) with a Overweight and maintains $10 price target.
2024-09-06 21:46